CRIS — Curis, Inc.

Is CRIS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Curis, Inc. (CRIS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.70. The rating moved from Neutral to Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

Curis, Inc. is a small-cap oncology/biotech issuer whose market value is driven predominantly by pipeline prospects and milestone events rather than recurring revenue. Financial health is typically constrained for companies at this stage, leaving the firm sensitive to cash runway and capital markets access; potential dilution is a key near-term concern. Competitive positioning depends on clinical differentiation and the ability to secure partnerships or non-dilutive financing. Short-term sector sentiment is mildly constructive, which can provide temporary support, but the stock remains highly volatile and event-driven. Downside scenarios include negative clinical or regulatory outcomes and the need for dilutive funding; upside requires clear clinical progress or strategic transactions that materially de-risk future commercialization pathways.

Key factors

  • Small-cap biotech with limited or no meaningful commercial revenue; valuation is primarily driven by clinical pipeline and financing dynamics
  • High dependence on upcoming clinical readouts and regulatory milestones which can create large binary moves in share price
  • Cash runway and potential need for dilution through equity raises or partnering/licensing transactions
  • Sector sentiment: near-term constructive risk-on tone in equities could provide temporary support to speculative biotech names
  • Limited liquidity and investor attention relative to larger biotech peers increases volatility and downside on negative news
  • Potential for upside if positive clinical data or a strategic partnership emerges, but probability of such events is uncertain

Risks

  • Clinical trial failure or unfavorable safety/efficacy readouts that materially reduce pipeline value
  • Dilutive financings required to fund operations, compressing existing shareholder value
  • Regulatory delays or adverse feedback from health authorities
  • Competitive advances from better-funded oncology or biologics developers eroding commercial prospects
  • Low trading liquidity increasing downside volatility and impairing orderly price discovery
  • Macro/market risk: a shift away from risk-on flows or a broader biotech selloff would disproportionately impact small-cap biotechs

See today's live rating, score and targets

Members see the live hourly rating for CRIS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.